CN111529645B - 一种治疗肾虚络瘀型糖尿病肾病ⅳ期的药物 - Google Patents
一种治疗肾虚络瘀型糖尿病肾病ⅳ期的药物 Download PDFInfo
- Publication number
- CN111529645B CN111529645B CN202010298259.4A CN202010298259A CN111529645B CN 111529645 B CN111529645 B CN 111529645B CN 202010298259 A CN202010298259 A CN 202010298259A CN 111529645 B CN111529645 B CN 111529645B
- Authority
- CN
- China
- Prior art keywords
- medicine
- stage
- kidney
- diabetic nephropathy
- effects
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 210000003734 kidney Anatomy 0.000 title claims abstract description 32
- 239000003814 drug Substances 0.000 title claims abstract description 30
- 208000007342 Diabetic Nephropathies Diseases 0.000 title claims abstract description 25
- 208000033679 diabetic kidney disease Diseases 0.000 title claims abstract description 25
- 230000007812 deficiency Effects 0.000 title claims abstract description 17
- 229940079593 drug Drugs 0.000 title description 3
- 241000208368 Euonymus alatus Species 0.000 claims abstract description 10
- 240000001659 Oldenlandia diffusa Species 0.000 claims abstract description 10
- 241000258241 Mantis Species 0.000 claims abstract description 9
- 241000237502 Ostreidae Species 0.000 claims abstract description 9
- 235000020636 oyster Nutrition 0.000 claims abstract description 9
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 claims abstract description 8
- 244000268590 Euryale ferox Species 0.000 claims abstract description 7
- 235000006487 Euryale ferox Nutrition 0.000 claims abstract description 7
- 240000006766 Cornus mas Species 0.000 claims abstract description 6
- 235000002722 Dioscorea batatas Nutrition 0.000 claims abstract description 5
- 235000006536 Dioscorea esculenta Nutrition 0.000 claims abstract description 5
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 claims abstract description 5
- 235000006533 astragalus Nutrition 0.000 claims abstract description 5
- 241000045403 Astragalus propinquus Species 0.000 claims abstract description 4
- 241000304195 Salvia miltiorrhiza Species 0.000 claims abstract 3
- 240000001811 Dioscorea oppositifolia Species 0.000 claims abstract 2
- 230000000694 effects Effects 0.000 abstract description 30
- 102000004169 proteins and genes Human genes 0.000 abstract description 12
- 108090000623 proteins and genes Proteins 0.000 abstract description 12
- 210000002700 urine Anatomy 0.000 abstract description 11
- 230000017531 blood circulation Effects 0.000 abstract description 10
- 230000003907 kidney function Effects 0.000 abstract description 7
- 244000020518 Carthamus tinctorius Species 0.000 abstract description 6
- 235000003255 Carthamus tinctorius Nutrition 0.000 abstract description 6
- 235000013399 edible fruits Nutrition 0.000 abstract description 6
- 244000046146 Pueraria lobata Species 0.000 abstract description 4
- 235000010575 Pueraria lobata Nutrition 0.000 abstract description 4
- 244000081426 Ranunculus ficaria Species 0.000 abstract description 4
- 235000002226 Ranunculus ficaria Nutrition 0.000 abstract description 4
- 241001278833 Rosa laevigata Species 0.000 abstract description 4
- 235000000661 Rosa laevigata Nutrition 0.000 abstract description 4
- 238000005728 strengthening Methods 0.000 abstract description 3
- 230000001988 toxicity Effects 0.000 abstract description 3
- 231100000419 toxicity Toxicity 0.000 abstract description 3
- 210000000582 semen Anatomy 0.000 abstract description 2
- 210000004369 blood Anatomy 0.000 description 17
- 239000008280 blood Substances 0.000 description 17
- 208000024891 symptom Diseases 0.000 description 10
- 238000011160 research Methods 0.000 description 9
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 206010030113 Oedema Diseases 0.000 description 6
- 210000000952 spleen Anatomy 0.000 description 6
- 230000006378 damage Effects 0.000 description 5
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 244000132619 red sage Species 0.000 description 5
- 244000096857 Dioscorea batatas Species 0.000 description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 208000002173 dizziness Diseases 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 4
- 208000006083 Hypokinesia Diseases 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 241000405414 Rehmannia Species 0.000 description 3
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 3
- 240000009022 Smilax rotundifolia Species 0.000 description 3
- 235000003205 Smilax rotundifolia Nutrition 0.000 description 3
- 206010047513 Vision blurred Diseases 0.000 description 3
- 208000031971 Yin Deficiency Diseases 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 206010022437 insomnia Diseases 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 229940126680 traditional chinese medicines Drugs 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 241000049624 Alisma plantago-aquatica subsp. orientale Species 0.000 description 2
- 206010007247 Carbuncle Diseases 0.000 description 2
- 240000005717 Dioscorea alata Species 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 2
- 229940107666 astragalus root Drugs 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 235000004879 dioscorea Nutrition 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 201000001474 proteinuria Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 description 1
- 241001061264 Astragalus Species 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 241000132012 Atractylodes Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 description 1
- 239000002053 C09CA06 - Candesartan Substances 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- 239000009636 Huang Qi Substances 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 102000001399 Kallikrein Human genes 0.000 description 1
- 108060005987 Kallikrein Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 208000016222 Pancreatic disease Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 240000007164 Salvia officinalis Species 0.000 description 1
- 206010067868 Skin mass Diseases 0.000 description 1
- 241001404789 Smilax glabra Species 0.000 description 1
- 208000004078 Snake Bites Diseases 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
- 229940126317 angiotensin II receptor antagonist Drugs 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- SGZAIDDFHDDFJU-UHFFFAOYSA-N candesartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SGZAIDDFHDDFJU-UHFFFAOYSA-N 0.000 description 1
- 229960000932 candesartan Drugs 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 208000004104 gestational diabetes Diseases 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229940039088 kininogenase Drugs 0.000 description 1
- 235000020997 lean meat Nutrition 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000020905 low-protein-diet Nutrition 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 229960000715 nimodipine Drugs 0.000 description 1
- 239000003538 oral antidiabetic agent Substances 0.000 description 1
- 229940127209 oral hypoglycaemic agent Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 208000024691 pancreas disease Diseases 0.000 description 1
- 206010034754 petechiae Diseases 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 235000021075 protein intake Nutrition 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 235000005412 red sage Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000008327 renal blood flow Effects 0.000 description 1
- 238000000518 rheometry Methods 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 210000004233 talus Anatomy 0.000 description 1
- 201000005665 thrombophilia Diseases 0.000 description 1
- 235000015961 tonic Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/19—Acanthaceae (Acanthus family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/37—Celastraceae (Staff-tree or Bittersweet family), e.g. tripterygium or spindletree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/40—Cornaceae (Dogwood family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/62—Nymphaeaceae (Water-lily family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/748—Oldenlandia or Hedyotis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/90—Smilacaceae (Catbrier family), e.g. greenbrier or sarsaparilla
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Insects & Arthropods (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Marine Sciences & Fisheries (AREA)
- Animal Husbandry (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
一种治疗肾虚络瘀型糖尿病肾病Ⅳ期的药物，其组成为：生黄芪25‑35g，生牡蛎25‑35g，土茯苓25‑35g，芡实25‑35g，蛇舌草13‑18g，鬼箭羽8‑15g，丹参8‑13g，生地8‑12g，山药7‑12g，山茱萸8‑12g，桑螵蛸5‑12g。本发明在滋膵益肾方基础上去玄参、苍术、葛根、红花、泽泻、金樱子，加用生牡蛎、蛇舌草、鬼箭羽、丹参、桑螵蛸而成，加强活血散结、祛瘀通络、清热解毒功效，从而达到改善肾功能，减少尿蛋白作用。
Description
技术领域
本发明涉及一种治疗肾虚络瘀型糖尿病肾病Ⅳ期的药物，具体地说是在经验方滋膵益肾方基础上加减方而成的药物。
背景技术
糖尿病肾病(diabetic nephropathy，DN)是糖尿病常见而难治的微血管并发症，是患者致死、致残主要原因之一。早期发现肾脏损害，寻求积极有效治疗手段，使DN(Ⅳ期)病情得到最大程度控制，对延缓患者病情发展，提高患者生活质量具有重大意义。现代研究表明，DN的发生发展与高血糖引起的蛋白非酶糖基化、高血黏度、血流动力学异常等密切相关。目前《中国2型糖尿病防治指南》推荐采用血管紧张素转化酶抑制剂和血管紧张素Ⅱ受体拮抗剂治疗DN(Ⅳ期)，同时改善血液高凝状态，改善氧化应激环境，尽管现代医学在治疗DN上已形成较规范的治疗方案，但疗效仍不理想，不能控制临床DN的自然进程。
DN(Ⅳ期)属中医学“下消”、“尿浊”、“水肿”等范畴。消渴病早期由于阴虚燥热，继而气阴两虚已成共识，而随之病情进展，气虚运血无力，阴虚血行艰涩，血液运行不畅，瘀血形成，久而伤及肾之络脉，从而导致DN的发生发展。脾肾亏虚，水湿浊邪内停，血脉壅滞，形成恶性循环。“血不利则为水”，瘀血阻滞脉络，致使脉内的津液不能输布，脉外的津液不能还流，或脏腑气化行水的功能失调，故见浮肿等症。总之，“脾肾亏损”、“肾失气化、封藏”、“瘀浊阻络”，导致精微物质下泄，肾精亏损，呈现本虚标实、虚实夹杂的病机，病程缠绵难愈。基本病机为正虚邪实，正虚以脾肾虚弱为主，邪实以风邪、水湿、湿热、瘀血为主。大量的临床研究已经证实中医药在减少DN蛋白漏出、改善肾功能方面具有相对明显的优势，尤其是根据DN病因病机，结合临床经验总结出治疗肾虚络瘀型糖尿病肾病(Ⅳ期)经验方滋脺益肾方，其对于改善患者腰酸、浮肿、头晕乏力等症状方面取得一定疗效，但在改善患者肾功能，减少尿蛋白方面，疗效仍有待提高。因此，寻求积极有效治疗手段，使DN肾功能损害得到最大程度控制，对延缓患者病情发展，改善远期预后具有重大意义。
发明内容
本发明的目的是提供一种治疗肾虚络瘀型糖尿病肾病Ⅳ期的药物，以进一步提高对肾虚络瘀型糖尿病肾病Ⅳ期的治疗效果。
为实现上述目的，本发明提供的药物是在滋膵益肾方加减而成，其组成为：
生黄芪25-35g，生牡蛎25-35g，土茯苓25-35g，芡实25-35g，蛇舌草13-18g，鬼箭羽8-15g，丹参8-13g，生地8-12g，山药7-12g，山茱萸8-12g，桑螵蛸5-12g。
优选的组成为：生黄芪30g，生牡蛎30g，土茯苓30g，芡实30g，蛇舌草15g，鬼箭羽10g，丹参10g，生地10g，山药10g，山茱萸10g，桑螵蛸10g。
本发明的药物为汤剂。
本发明在滋膵益肾方基础上去玄参、苍术、葛根、红花、泽泻、金樱子，加用生牡蛎、蛇舌草、鬼箭羽、丹参、桑螵蛸而成，加强活血散结、祛瘀通络、清热解毒功效，从而达到改善肾功能，减少尿蛋白作用。
具体实施方式
本发明是在滋膵益肾方基础上去玄参、苍术、葛根、红花、泽泻、金樱子，加用生牡蛎、蛇舌草、鬼箭羽、丹参、桑螵蛸而成。
滋膵益肾方重用黄芪以益气培本，兼能利水；山茱萸、山药固肾补脾，加之生地黄、玄参滋肾清热，苍术健脾燥湿、固本降糖，葛根健脾升阳；芡实、金樱子同用益肾涩精；红花活血通络；土茯苓、泽泻化湿热、利水泄浊，令补益药补而不滞。现代药理研究表明，黄芪具有扩张血管，增加肾血流量，抑制血小板聚集，调节免疫，减少尿蛋白，保护肾脏的作用；土茯苓、金樱子、芡实合用具有固本治标，降低蛋白尿的目的。
本发明是基于中国中医学对糖尿病肾病机理的认识和治疗原则，参考现代药理研究成果，在滋膵益肾方基础上去玄参、苍术、葛根、红花、泽泻、金樱子，加用生牡蛎、蛇舌草、鬼箭羽、丹参、桑螵蛸等五味中药而成，加强活血散结、祛瘀通络、清热解毒功效，从而达到改善肾功能，减少尿蛋白作用。
本发明加入的五味中药中：
生牡蛎：入少阴肾经，具有软坚散结、潜阳补阴等功效，用于瘰疬痰核，症瘕痞块等，与黄芪合用为君，加强补肾正气、散结消症作用。
蛇舌草：功效为清热解毒、消痈，临床用于痈肿疮毒，咽喉肿痛、毒蛇咬伤等症。现代药理研究，有抗菌消炎的作用。能增强机体免疫功能，增强白细胞吞噬功能，较多临床试验证实具有较好的减少尿蛋白作用。
鬼箭羽：为消渴病常用活血药物之一，具有破血散结，同时具有降血糖、改善胰岛素抵抗功效。
丹参：为活血化瘀之要药，现代研究认为有抗凝，促进纤溶，降血脂，抑制粥样斑块形成，增强免疫作用。
桑螵蛸：补肾助阳、固精缩尿，与芡实、生地、山药、山茱萸等同服，加强补肾固涩，同时滋肾阴、补肾阳，阴阳兼顾。
本发明在滋膵益肾方加减而成的药物全方消补同用、阴阳兼顾、标本兼治，共奏补肾活血、散结通络之功。
以下进一步说明本发明的药物对肾虚络瘀型糖尿病肾病Ⅳ期的治疗方法和效果：
1、疾病的诊断标准：西医诊断标准参照1999年WHO公布的糖尿病诊断标准，确诊为2型糖尿病；DN(Ⅳ期)参照Mogensen对DN的分期，尿白蛋白排出率(urinary albuminexcretion rate，UAER)>200μg/min，或24h尿蛋白>0.5g。中医证候标准参照《中药新药临床研究指导原则(试行)》。肾虚络瘀型：腰酸乏力，浮肿头晕，视物模糊，定位刺痛，口干唇燥，失眠心烦，面色晦暗，泡沫尿，舌暗红或暗淡，或有瘀点，脉弦细或沉细。
2、病例的选择：
2.1纳入标准
①年龄30-70岁，男女不限；
②服用类似本方案药物作用的中药患者需停用中药1个月后方可纳入；
③能明确本试验的研究目的和过程，同意并积极配合本临床试验要求，并自愿签署知情同意书者。
2.2排除标准
①1型糖尿病、妊娠糖尿病以及各种胰腺疾病、肝脏疾病、内分泌疾病等继发糖尿病所致的肾病；
②其他如发热、各种感染、运动、心功能不全、原发性肾脏病等原因引起的蛋白尿；
③合并严重高血压、肝功能损害、肾功能损害、心力衰竭、肿瘤等严重疾病者；
④具有精神疾病患者。
3、用药方法；
基础治疗
①优质低蛋白饮食(如牛奶、蛋类以及鱼类、瘦肉等蛋白；)：蛋白质摄入量为每日0.8g/kg；
②控制血糖：口服降糖药，和(或)注射胰岛素，使空腹血糖≤7.0mmol/L，餐后2h血糖≤10.0mmol/L，以达到《中国2型糖尿病防治指南》标准；
③降低血压：坎地沙坦8mg，每日1次，口服。将收缩压控制在90～130mmHg，将舒张压控制在60～80mmHg。
(1)对照组胰激肽原酶肠溶片120单位，每日3次，口服。
(2)治疗组1滋膵益肾方口服(生黄芪、芡实、金樱子、土茯苓各30g，葛根20g，生地黄、山茱萸、山药、玄参、苍术、泽泻各15g，红花6g)。
(3)治疗组2本发明滋膵益肾方加减方口服(生黄芪、生牡蛎、土茯苓、芡实各30g，蛇舌草15g，鬼箭羽、丹参、生地、山药、山茱萸、桑螵蛸各10g)。
统一由煎药机专人煎取，并作质量控制，每日1剂，煎取两袋，每袋100mL，早晚各1袋，饭后30min温服。疗程均为8周。
4、观察指标：
(1)临床症状评分参考《中药新药临床研究指导原则》，将患者浮肿、乏力、腰酸、头晕、视物模糊、定位刺痛、心悸、失眠8个临床症状，根据无、轻、中、重4个等级分别计为0、2、4、6分。
(2)检测指标包括肌酐、尿素氮、24h尿蛋白定量、血液流变学指标(血浆黏度)。治疗开始和结束时各检测1次。
5、疗效判定标准：
中医证候疗效判定标准：根据《中药新药临床研究指导原则》制定中医证候疗效判定标准，先采用尼莫地平法计算疗效指数
疗效指数＝(治疗前积分－治疗后积分)/治疗前积分×100％。
临床痊愈：临床症状(浮肿、乏力、腰酸、头晕、视物模糊、定位刺痛、心悸、失眠)减轻，疗效指数≥90％；
显效；临床症状明显改善，70％≤疗效指数＜90％；
有效：临床症状均有好转，30％≤疗效指数＜70％；
无效：临床症状无明显改善，甚或加重，疗效指数＜30％。
6、疾病总体的治疗结果；
(1)各组中医证候疗效比较见表1。
(2)各组患者肌酐、尿素氮、24小时尿蛋白以及血粘度水平比较见表2。
表1
与对照组比较##p<0.01，与治疗组1比较*p<0.05。
表2
注：与同组治疗前比较，*P<0.05，**P<0.01；治疗组2差值与对照组差值比较，#P<0.05，##P<0.01；治疗组2差值与治疗组1差值比较，△P<0.05，△△P<0.01。
Claims (2)
1.一种治疗肾虚络瘀型糖尿病肾病Ⅳ期的药物，其组成为：
生黄芪30g，生牡蛎30g，土茯苓30g，芡实30g，蛇舌草15g，鬼箭羽10g，丹参10g，生地10g，山药10g，山茱萸10g，桑螵蛸10g。
2.根据权利要求1所述的药物，其中，所述药物为汤剂。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010298259.4A CN111529645B (zh) | 2020-04-16 | 2020-04-16 | 一种治疗肾虚络瘀型糖尿病肾病ⅳ期的药物 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010298259.4A CN111529645B (zh) | 2020-04-16 | 2020-04-16 | 一种治疗肾虚络瘀型糖尿病肾病ⅳ期的药物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111529645A CN111529645A (zh) | 2020-08-14 |
| CN111529645B true CN111529645B (zh) | 2022-03-15 |
Family
ID=71970562
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010298259.4A Expired - Fee Related CN111529645B (zh) | 2020-04-16 | 2020-04-16 | 一种治疗肾虚络瘀型糖尿病肾病ⅳ期的药物 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111529645B (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113730520B (zh) * | 2021-09-30 | 2022-06-10 | 上海市第七人民医院(上海中医药大学附属第七人民医院) | 一种治疗糖尿病肾病蛋白尿的中药组合 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101940716A (zh) * | 2010-09-19 | 2011-01-12 | 薛红云 | 一种治疗糖尿病肾病的药物 |
| CN107737279A (zh) * | 2017-11-21 | 2018-02-27 | 武汉大学 | 一种治疗糖尿病肾病的中药配方及其制备方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102641430B (zh) * | 2012-05-05 | 2013-09-11 | 刘健 | 一种治疗糖尿病肾病的中药汤剂 |
-
2020
- 2020-04-16 CN CN202010298259.4A patent/CN111529645B/zh not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101940716A (zh) * | 2010-09-19 | 2011-01-12 | 薛红云 | 一种治疗糖尿病肾病的药物 |
| CN107737279A (zh) * | 2017-11-21 | 2018-02-27 | 武汉大学 | 一种治疗糖尿病肾病的中药配方及其制备方法 |
Non-Patent Citations (2)
| Title |
|---|
| 健脾益肾清化汤治疗早中期糖尿病肾病蛋白尿的临床观察;冯珍凤等;《中医药信息》;20200331;第37卷(第2期);第99-102页 * |
| 滋益肾方治疗肾虚络瘀型糖尿病肾病Ⅳ期临床研究;胡春平等;《安徽中医药大学学报》;20151231;第34卷(第06期);第15-18页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111529645A (zh) | 2020-08-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20180055898A1 (en) | Traditional chinese medicine composition for preventing and treating externally diabetes and a method of using the same | |
| CN102048897B (zh) | 治疗老年习惯性便秘的中药制剂 | |
| CN104225441A (zh) | 一种治疗胃病的中药组合物及其颗粒剂和胶囊剂的制备方法 | |
| CN103127420A (zh) | 一种治疗慢性肾小球肾炎的中药组合物 | |
| CN102743540A (zh) | 联合降糖方 | |
| CN104524337A (zh) | 一种治疗口腔溃疡的中药 | |
| CN102058784A (zh) | 一种治疗肺心病的药物组合物及其用途 | |
| CN111529645B (zh) | 一种治疗肾虚络瘀型糖尿病肾病ⅳ期的药物 | |
| CN102512552B (zh) | 一种治疗外感发热的中药组合物 | |
| CN102225190A (zh) | 一种治疗慢性结肠炎的中药制剂 | |
| CN102579610B (zh) | 一种治疗脑出血的中药组合物及其制备方法 | |
| CN101428114B (zh) | 一种治疗慢性乙肝、肝硬化和肝腹水的药物 | |
| CN103330868A (zh) | 一种慢性肾衰竭用肠道给液 | |
| CN103041145B (zh) | 一种治疗外感发热的中药组合物 | |
| CN115770279A (zh) | 用于治疗慢性下肢静脉疾病的中药组合物及其汤剂和制剂 | |
| CN103211973B (zh) | 一种治疗慢性放射性直肠炎的中药制剂 | |
| CN102441154A (zh) | 一种治疗痛风的中药制剂 | |
| CN103520319A (zh) | 一种治疗慢性肾炎的中药 | |
| CN101085247A (zh) | 治疗肾炎及尿毒症的药物及其制备方法 | |
| CN102406743A (zh) | 一种治疗脑血栓的中药制剂 | |
| CN104771741A (zh) | 一种治疗慢性肠炎的中药组合物 | |
| CN101543581B (zh) | 消斑口服液 | |
| CN104367753A (zh) | 一种治疗2型糖尿病的中药组合物 | |
| CN103386055A (zh) | 一种前列安通胶囊及制备方法 | |
| CN103536866A (zh) | 一种治疗腹部手术后炎性肠梗阻的中药组合物及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20220315 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |